InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (10 ops.)
Discover the full record of transactions filed by Rawcliffe Adrian, Chief Executive Officer. Director active across 1 companies, notably Adaptimmune Therapeutics PLC. In total, 10 filings have been logged. Total volume traded: €237k. The latest transaction was disclosed on 18 January 2022 (Cession). Regulator: SEC (Form 4). The full history is free.
Declarations10 total
€31,03811,096 shares@ €2.797226.2% of flow
American Depositary Shares representing Ordinary Shares
SEC:0001104659-22-005053·
€31,03811,096 shares@ €2.797213.1% of flow
American Depositary Shares representing Ordinary Shares
SEC:0001104659-22-005053:0·
€45,08314,362 shares@ €3.139138.1% of flow
American Depositary Shares representing Ordinary Shares
SEC:0001104659-22-004149·
€45,08314,362 shares@ €3.139119.0% of flow
American Depositary Shares representing Ordinary Shares
SEC:0001104659-22-004149:0·
€19,8935,532 shares@ €3.595916.8% of flow
American Depositary Shares representing Ordinary Shares
SEC:0001104659-22-001668·
€19,8935,532 shares@ €3.59598.4% of flow
American Depositary Shares representing Ordinary Shares
SEC:0001104659-22-001668:0·
€12,2062,782 shares@ €4.387310.3% of flow
American Depositary Shares representing Ordinary Shares
SEC:0001104659-21-112179·
€12,2062,782 shares@ €4.38735.2% of flow
American Depositary Shares representing Ordinary Shares
SEC:0001104659-21-112179:0·
€10,2352,794 shares@ €3.66348.6% of flow
American Depositary Shares representing Ordinary Shares
SEC:0001104659-21-086385·
€10,2352,794 shares@ €3.66344.3% of flow
American Depositary Shares representing Ordinary Shares
SEC:0001104659-21-086385:0·
10 of 10 declarations
About Rawcliffe Adrian
Adrian Rawcliffe is the Chief Executive Officer at Adaptimmune Therapeutics PLC. He leads the company's operations and strategy, focusing on the development of innovative immunotherapy therapies. With significant experience in the biopharmaceutical sector, Adrian is responsible for overseeing research and development initiatives and commercial growth at Adaptimmune. His leadership is essential to position the company as a leader in the field of cell therapies.
